Arbutus BiopharmaABUS
About: Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Employees: 44
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
60% more call options, than puts
Call options by funds: $2.44M | Put options by funds: $1.53M
55% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 42
3.1% more ownership
Funds ownership: 58.38% [Q1] → 61.48% (+3.1%) [Q2]
5% less funds holding
Funds holding: 167 [Q1] → 159 (-8) [Q2]
7% less capital invested
Capital invested by funds: $390M [Q1] → $364M (-$26M) [Q2]
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
40% less funds holding in top 10
Funds holding in top 10: 5 [Q1] → 3 (-2) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Chardan Capital Keay Nakae | 37%upside $5 | Buy Maintained | 11 Aug 2025 |
Financial journalist opinion
Based on 3 articles about ABUS published over the past 30 days
